These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23034010)

  • 1. Response letter to D. Singh-franco et al.
    Owens DR; Del Prato S; Taskinen MR; Gomis R; Forst T; Woerle HJ
    Diabetes Obes Metab; 2012 Nov; 14(11):1054-5. PubMed ID: 23034010
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Singh-Franco D; McLaughlin-Middlekauff J; Elrod S; Harrington C
    Diabetes Obes Metab; 2012 Aug; 14(8):694-708. PubMed ID: 22340363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linagliptin (Tradjenta)--a new DPP-4 inhibitor for type 2 diabetes.
    Med Lett Drugs Ther; 2011 Jun; 53(1367):49-50. PubMed ID: 21701440
    [No Abstract]   [Full Text] [Related]  

  • 4. [Oral Linagliptin (Trajenta)].
    Duh D; Tanret I
    J Pharm Belg; 2013 Mar; (1):41-3. PubMed ID: 23638612
    [No Abstract]   [Full Text] [Related]  

  • 5. Jentadueto XR for type 2 diabetes.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):98-100. PubMed ID: 27466749
    [No Abstract]   [Full Text] [Related]  

  • 6. [Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2013 Sep; 68(9):479-85. PubMed ID: 24180204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oral antidiabetic drugs in chronic renal disease].
    Somogyi A
    Orv Hetil; 2012 Nov; 153(44):1727-31. PubMed ID: 23103741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualised incretin-based treatment for type 2 diabetes.
    Nauck MA; Meier JJ
    Lancet; 2010 Aug; 376(9739):393-4. PubMed ID: 20580425
    [No Abstract]   [Full Text] [Related]  

  • 9. [Novel combined glucose-lowering drug with DPP-4 inhibitor and pioglitazone].
    Fujita Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():642-6. PubMed ID: 22768591
    [No Abstract]   [Full Text] [Related]  

  • 10. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R
    Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.
    Patel CG; Kornhauser D; Vachharajani N; Komoroski B; Brenner E; Handschuh del Corral M; Li L; Boulton DW
    Diabetes Obes Metab; 2011 Jul; 13(7):604-14. PubMed ID: 21332626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin.
    Currie CJ; Holden SE
    Diabetes Obes Metab; 2014 Oct; 16(10):881-4. PubMed ID: 25040702
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.
    Rosenstock J; Lewin AJ; Norwood P; Somayaji V; Nguyen TT; Teeter JG; Johnson SL; Dai H; Terra SG
    Diabet Med; 2011 Apr; 28(4):464-9. PubMed ID: 21392067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Toth PP
    Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13(3): 193-203.
    Carr RD; Katzeff HL; Alexander CM; Berger JP; Xu SS; Thornberry N
    Diabetes Obes Metab; 2012 Apr; 14(4):383-4. PubMed ID: 22390829
    [No Abstract]   [Full Text] [Related]  

  • 18. Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia.
    Haak T
    Adv Ther; 2012 Dec; 29(12):1005-15. PubMed ID: 23212658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
    Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
    Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.
    Tornio A; Niemi M; Neuvonen PJ; Backman JT
    Trends Pharmacol Sci; 2012 Jun; 33(6):312-22. PubMed ID: 22475684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.